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Abstract: Pulmonary arterial hypertension (PAH) is a life-threatening disease which, if 
untreated, leads to right ventricular failure and often death. Several effective therapies are now 
available for PAH, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and 
prostacyclin analogs. The prostacyclin analog treprostinil has proven efficacious when delivered 
by subcutaneous or intravenous infusion, and most recently by inhalation. Inhaled treprostinil 
has been shown to be 64%–72% bioavailable in healthy volunteers. Pilot clinical studies have 
elucidated the acute hemodynamic effects and relative pulmonary selectivity of this agent, 
as well as established target dosing in PAH and nonoperable chronic thromboembolic PAH. 
Likewise, chronically administered inhaled treprostinil resulted in clinical and hemodynamic 
improvement. Both pilot studies confirmed a satisfactory safety profile in patients with PAH. 
The pivotal Phase III trial, TRIUMPH-I, demonstrated the efficacy and safety of inhaled trepro-
stinil (target dose of 54 µg four times daily) in PAH patients added to background therapies of 
bosentan or sildenafil, as assessed by improvements in the primary endpoint, peak six-minute 
walk distance (median placebo-corrected treatment effect of 20 m), as well as select secondary 
endpoints. Inhaled treprostinil is approved by the US Food and Drug Administration for patients 
with World Health Organization Group I PAH to improve exercise ability. Studies establishing 
effectiveness included predominately patients with New York Heart Association functional 
class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with 
connective tissue diseases (33%).
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Introduction
Pulmonary arterial hypertension (PAH) is a life-threatening disorder characterized 
by a widespread pulmonary vasculopathy, leading to elevation in pulmonary arterial 
pressure (PAP) and resultant right ventricular enlargement and dysfunction. Without 
therapy, death from progressive right ventricular failure is common.1 During the 
last 20 years, the development of PAH-specific therapies has led to both short- and 
long-term benefits to many patients. These “targeted” treatments were discovered by 
disrupting the normal balance of important mediators of pulmonary vasomotor tone and 
growth, including endothelin-1, nitric oxide, and prostacyclin. This “bench-to-bedside” 
translation has led to the approval of three classes of PAH therapies: endothelin receptor 
antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE-5Is), and prostacyclin 
analogs (Table 1).
The clinical development of currently approved therapies for PAH has followed a 
traditional path. Preclinical testing to demonstrate drug safety and activity has been Drug Design, Development and Therapy 2012:6 submit your manuscript | www.dovepress.com
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followed by Phase I and II studies which typically include 
dose finding and preliminary indication of efficacy.   Positive 
results in Phase II, have traditionally led to larger scale 
Phase III randomized, controlled trials with most often a 
primary endpoint of improvement in exercise capacity.2–9 
In fact, most all of the currently approved PAH therapies 
have received their initial regulatory approval as monotherapy 
for the primary indication by improving six-minute walk 
distance (6MWD). Additional endpoints such as functional 
class, hemodynamics, and clinical worsening of PAH have 
also been included in most of these Phase III trials.
Given the availability of several therapies and routes 
of administration, the selection and timing of appropriate 
treatment(s) have become more complex. Various consensus 
guidelines have been developed to guide these decisions.10–12 
Of the three classes of PAH therapies, parenteral prostacy-
clin analogs have been the most widely studied. Intravenous 
epoprostenol was the first US Food and Drug Administration 
(FDA)-approved treatment for PAH based on significant 
improvement of exercise capacity and significant reduction 
of mortality after 12 weeks.2 However, due to its extremely 
short in vitro half-life (less than 6 min in human blood at 
37°C and pH 7.4), epoprostenol must be delivered as a con-
tinuous intravenous infusion through an indwelling catheter, 
with the risk of rebound PAH and acute right heart failure 
in case of infusion interruption. Furthermore, due to the 
inherent chemical instability of one form of epoprostenol 
(FLOLAN®; GlaxoSmithKline, Research Triangle Park, 
NC) at room temperature and neutral pH, ice packs may 
be needed to slow decomposition throughout the infusion 
period. A thermostable epoprostenol preparation for infu-
sion (VELETRI®; Actelion Pharmaceuticals US, Inc, San 
Francisco, CA), which does not require cooling, has recently 
been approved for use by the FDA.
To address these potential limitations of epoprostenol, 
longer-acting prostacyclin analogs have been developed, 
including iloprost and treprostinil. These agents have, with 
regional global differences, been approved for intravenous 
infusion (iloprost is not approved in the US for intravenous 
route) and, in the case of treprostinil, subcutaneous   infusion. 
The pharmacological and physiochemical properties of 
iloprost and treprostinil also make both agents amenable to 
intermittent administration via the inhaled route using ultra-
sonic nebulizers specific to each therapy. Data have emerged 
confirming the benefit of using inhaled prostacyclin analogs 
for PAH therapy.4,13
This review focuses on the clinical development of 
inhaled treprostinil. Pharmacological aspects of this agent 
and currently available preclinical pharmacology and clinical 
data will be discussed. A perspective on the role of inhaled 
treprostinil for PAH is also discussed.
Preclinical pharmacology  
and pharmacokinetics
Treprostinil is a chemically stable tricyclic benzindene pros-
tanoid with a molecular weight of 390.52 and a molecular 
formula of C23H34 NaO5 (Figure 1). Inhaled treprostinil was 
first tested in a sheep model of pulmonary hypertension: 
  Following a PGH2 analog, which caused marked pulmonary 
vasoconstriction, inhaled treprostinil completely normalized 
pulmonary vascular resistance (PVR) with minimal systemic 
blood pressure effects.14
Unlike epoprostenol which has an in vitro half-life of 
less than 6 min in human blood, treprostinil has an in vivo 
terminal elimination half-life of 4.6 hours following continu-
ous subcutaneous infusion in normal volunteers.15 In vitro, 
91% of treprostinil is bound to human plasma proteins. No 
Table 1   FDA-approved  therapies  for  pulmonary  arterial 
hypertension
Prostacyclin analogs
epoprostenol: intravenous
iloprost: inhaled
Treprostinil: subcutaneous, intravenous, inhaled
Endothelin receptor antagonists
Bosentan: oral
Ambrisentan: oral
Phosphodiesterase-5 inhibitors
Sildenafil: oral, intravenous
Tadalafil: oral
O
O
HO
HO
H
H
OH
Figure  1  Structural  formula  of  treprostinil.  Treprostinil  is  (1R,2R,3aS,9aS)-
[[2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1Hbenz[f]inden-5-
yl]oxy]acetic acid. Treprostinil has a molecular weight of 390.52 and a molecular 
formula of C23H34O5.Drug Design, Development and Therapy 2012:6 submit your manuscript | www.dovepress.com
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effect on digoxin or warfarin displacement was detected. 
Treprostinil undergoes extensive oxidative metabolism in the 
liver, primarily by CYP2C8 and to a lesser extent CYP2C9. 
When subcutaneously administered, only 4% of treprostinil 
is excreted unchanged in urine. Although several urinary 
metabolites have been identified, none possess significant 
pharmacologic activity. No significant pharmacokinetic 
interactions have been found with treprostinil ethanolamine 
when administered orally with bosentan or sildenafil, which 
are commonly used agents in treating PAH.16
In two pilot studies with PAH patients, detectable levels 
of treprostinil were found in the systemic circulation follow-
ing inhalation.17,18 The bioavailability of inhaled treprostinil 
was evaluated in 18 healthy volunteers using a three-period 
crossover study design comparing two doses of inhaled 
treprostinil (18 and 36 µg) and intravenous treprostinil.19 
The two doses achieved 64% and 72% bioavailability, 
  respectively. The mean maximum plasma concentration 
(Cmax) for the 18 µg and 36 µg doses were 354 and 698 pg/mL, 
respectively, with a time to maximum plasma concentration 
(Tmax) of 0.15 hours. Treprostinil remained detectable in the 
plasma for up to 3.5 hours after inhalation.
A Phase I single dose escalation study in healthy vol-
unteers (n = 40) showed that the maximum tolerated dose 
of inhaled treprostinil sodium was 84 µg (14 breaths).19 
The pharmacokinetic parameters, Cmax (Figure 2) and area 
under the curve (AUC) generally increased with increas-
ing dose between 54 to 90 µg. The mean Cmax at the FDA 
recommended human dosage of 54 µg (nine breaths) 
dose was 0.91 ng/mL with a corresponding mean Tmax 
of 0.21 hours. The mean AUC for the 54 µg dose was 
0.81 ng-hr/mL, respectively. Studies of treprostinil admin-
istered by subcutaneous or intravenous infusion have shown 
that the elimination of treprostinil is biphasic, with a terminal 
elimination half-life of 4.4 and 4.6 hours, respectively.15 Given 
the relatively low systemic plasma concentrations achieved 
following treprostinil inhalation, a multicompartment model 
cannot be applied and, therefore, the terminal elimination 
half-life cannot be estimated. Analysis of the data obtained 
from a Phase I single dose escalation study (n = 40) of inhaled 
treprostinil using a noncompartmental model provided an 
estimate of the apparent half-life for treprostinil that ranged 
from 0.54 to 0.76 hours (Figure 2).
Clinical uses
Treprostinil was initially studied as a continuous subcutaneous 
infusion. In a pivotal 12 week randomized, controlled trial of 
470 patients, subcutaneous treprostinil significantly improved 
exercise capacity compared with placebo.3 The between 
treatment group difference in median 6MWD was 16 meters 
(P = 0.006). Importantly, the effect on exercise capacity 
appeared to be dose-dependent. A long-term follow-up study 
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of 806 patients reported by Barst and colleagues20 confirmed 
the durability of effect of subcutaneous treprostinil, with 
favorable survival compared to historical controls. One par-
ticular adverse effect, infusion site pain, led to discontinuation 
of drug in 8% of subcutaneous treprostinil-treated patients. 
Mathier and colleagues21 have summarized numerous practical 
considerations related to achieving symptomatic pain relief 
while using subcutaneous treprostinil. Although most often 
manageable, the frequency of infusion site pain led ultimately 
to the development and FDA approval of treprostinil as a 
continuous IV infusion. The efficacy of IV treprostinil was 
demonstrated in a 16-week open-label trial of 16 patients22 
followed by a 44 patient randomized placebo-controlled trial 
that demonstrated improvement in 6MWD.23
Clinical data of inhaled treprostinil
Treprostinil delivered intermittently to the pulmonary cir-
culation, ie, four times daily via inhalation using an Opti-
Neb ultrasonic nebulizer (NebuTec, Elsenfeld, Germany) 
(  Figure 3) appears to be an effective treatment for PAH. 
Given treprostinil’s longer half-life and its relative selectiv-
ity for the pulmonary circulation as compared to iloprost,17 
there was a strong rationale for developing treprostinil for 
inhalation. The ability of modern ultrasonic nebulizers to 
decrease and control particle size make these devices ideal 
for delivering prostacyclin analogs to the distal airspaces, 
which are in close proximity to the resistance pulmonary 
arterioles.
The first published human study of inhaled treprostinil 
was a hemodynamic study in three treatment-naïve patients 
with severe PAH.24 A single dose of 15 µg resulted in a reduc-
tion in PVR of approximately 45%. One of these patients had 
an excellent vasodilator response and was further treated with 
high-dose calcium channel blockers. Two of these patients 
continued therapy with reported improvements in exercise 
capacity and functional class.
A follow-up pilot study, comprising acute hemody-
namic and pharmacokinetic investigations, was conducted 
by Voswinckel and colleagues17 and compared the effects 
of inhaled treprostinil and inhaled iloprost in a crossover 
design (Figure 4). It was found that both agents resulted 
in comparable maximal decreases in PVR. However, the 
peak effect of inhaled treprostinil occurred later than with 
inhaled iloprost (18 ± 2 vs 8 ± 1 min). The duration of the 
treprostinil effect (after 60 minutes postinhalation, PVR was 
not back to baseline) was longer as compared to the iloprost 
effect (after 60 minutes postinhalation, PVR had returned to 
baseline). In addition, these investigators found that: (1) the 
maximal acute hemodynamic effect was seen at a dose of 
30 µg of inhaled treprostinil with a duration of effect lasting 
as long as three hours; (2) this dose could be safely delivered 
in one inhalation; and (3) doses up to 60 µg could be safely 
delivered in one single inhalation. These data confirmed 
the potent and sustained nature of inhaled treprostinil as a 
pulmonary vasodilator.
Voswinckel and colleagues25 also investigated the safety 
and acute hemodynamic effects of the combination of single 
doses of oral sildenafil (50 mg) and inhaled treprostinil (15 
or 30 µg) in an open-label study in patients with precapillary 
pulmonary hypertension. Compared to baseline, oral sildena-
fil reduced PVR to 80.1% ± 5.0%, mean PAP to 86.5% ± 2.9% 
and increased CO to 103.8% ± 3.2%. Treprostinil, inhaled one 
hour after sildenafil, reduced PVR further to 66.3% ± 3.8%, 
mean PAP to 77.8% ± 3.3%, and increased CO to 107.1% 
± 3.3% (mean ± 95% confidence interval). Subgroup analy-
sis showed similar acute hemodynamic effects in PAH and 
chronic thromboembolic pulmonary hypertension (CTEPH) 
patients. Ventilation/perfusion distribution measurement in 
six patients with preexisting gas exchange limitations was not 
Figure 3 Tyvaso inhalation System. Tyvaso is intended for oral inhalation using 
the Tyvaso inhalation System, which consists of the Opti-Neb-ir Model ON-100/7 
(NebuTec, elsenfeld, Germany), an ultrasonic, pulsed-delivery device.Drug Design, Development and Therapy 2012:6 submit your manuscript | www.dovepress.com
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changed by sildenafil and treprostinil. Relevant side effects 
were not observed. Thus, the combination of sildenafil and 
inhaled treprostinil appeared to be well-tolerated and induced 
additive, pulmonary selective vasodilatation in pulmonary 
hypertension patients.
Given that hemodynamic effects following acute dosing 
do not always correlate with long term clinical benefits, addi-
tional long-term efficacy studies were conducted, including 
evaluation as an add-on therapy to oral PAH medications. 
Channick and colleagues conducted a pilot, 12-week open 
label trial evaluating the efficacy and safety of two doses of 
inhaled treprostinil in 12 patients with PAH concurrently 
receiving bosentan.18 Patients were treated with 30 µg (n = 6) 
or 45 µg (n = 6) four times daily.   Hemodynamics, exercise 
capacity, functional class, pharmacokinetics, and safety were 
assessed. Acutely, inhaled treprostinil decreased mean PAP 
in a dose-dependent manner. Additionally, the study demon-
strated that inhaled treprostinil given chronically was well-
tolerated with an acceptable safety profile with common side 
effects including transient cough (n = 5), headache (n = 4), 
and sore throat (n = 2), but no serious adverse events. Hemo-
dynamics were improved, with significant decreases noted in 
mean PAP (10% decrease measured at peak postinhalation, 
approximately one hour) and a trend toward improvement 
in cardiac index (15% increase) and PVR (26% decrease). 
Significant improvements in both peak (67 meters) and trough 
(49 meters) 6MWDs were noted. Nine of 11 patients noted 
improvement in functional class from III to II.
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Figure 4 Comparison of acute hemodynamic effects of inhaled treprostinil and inhaled iloprost in patients with pulmonary arterial hypertension.17
Abbreviations: CO, cardiac output; PAP, pulmonary artery pressure; PvR, pulmonary vascular resistance; SAP, systemic artery pressure.
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Given the positive results from these pilot studies, 
a randomized placebo-controlled trial was conducted 
(TRIUMPH-I; TReprostinil Sodium Inhalation Used in the 
Management of Pulmonary Arterial Hypertension).13 Two 
hundred thirty-five PAH patients, with persistent WHO 
functional class III and IV symptoms despite receiving 
oral bosentan or sildenafil for at least three months, were 
randomized to receive either inhaled treprostinil (nine inha-
lations, 54 µg four times daily) or placebo, delivered via the 
Opti-Neb nebulizer. The primary endpoint was the 12-week 
placebo-corrected median change in peak (obtained 10 to 
60 minutes postinhalation) 6MWD compared to baseline. 
Secondary endpoints included time to clinical worsening 
(death, transplantation, hospitalization due to worsening 
PAH, or initiation of additional approved PAH-specific 
therapy), functional class, quality of life measures, trough 
6MWD, and N-terminal pro-brain natriuretic peptide   
(NT-proBNP) levels.
Baseline characteristics of the patients in TRIUMPH-I 
are shown in Table 2, demonstrated that patients were still 
quite symptomatic with impairment in function and exercise 
capacity despite being on a stable dose of either bosentan 
(125 mg bid) or sildenafil ($20 mg tid) for at least three 
months. At the end of 12 weeks, there was a highly significant 
(P = 0.0004) 20 m placebo-corrected median improvement 
in 6MWD. Not surprisingly, there was a distribution of effect 
on 6MWD (Figure 6). Fifty-two percent of patients receiving 
treprostinil for 12 weeks had improvements of 20 m or more, 
while 31% of treprostinil-treated patients walked 50 m or 
more compared with baseline.
The secondary endpoints of time to clinical   worsening, 
Borg dyspnea score, and New York Heart Association 
(NYHA) functional class were not significantly improved by 
inhaled treprostinil, most likely owing to the short duration of 
this 12 week study and that patients were on stable doses of 
bosentan or sildenafil monotherapy. Despite this, Minnesota 
Living with Heart Failure (MLWHF) questionnaire global and 
physical quality of life scores were improved (P = 0.027 and 
0.037, respectively for median between-treatment difference), 
as were plasma NT-proBNP levels (-187 pg/mL at week 12, 
P = 0.0014). Importantly, trough 6MWD (conducted prior to 
the next scheduled inhalation . four hours) was significantly 
improved in the treprostinil group compared to placebo 
(median 14-m treatment effect, P = 0.0066), suggesting a 
sustained effect of the medication.
Overall treatment with treprostinil for 12 weeks was fairly 
well-tolerated. The most commonly occurring adverse events 
are summarized in Table 3.
Indications and usage
Based on the results of the TRIUMPH-I study, on July 30, 
2009 inhaled treprostinil received FDA approval under the 
trade name Tyvaso (United Therapeutics Corporation, Silver 
Spring, MD). As of February 8, 2011, Tyvaso is indicated for 
the treatment of PAH (WHO Group 1) to improve exercise 
ability. Studies establishing effectiveness included predomi-
nately patients with NYHA functional class III symptoms 
and etiologies of idiopathic or heritable PAH (56%) or PAH 
associated with connective tissue diseases (33%). The effects 
diminish over the minimum recommended dosing interval 
of four hours; treatment timing can be adjusted for planned 
activities. While there are long-term data on use of trepros-
tinil by other routes of administration, nearly all controlled 
clinical experience with inhaled treprostinil has been on a 
background of bosentan (an endothelin receptor antagonist) 
or sildenafil (a PDE-5I). The controlled clinical experience 
was limited to 12 weeks in duration.
Dosage and administration
Usual dosage in adults
Tyvaso is intended for oral inhalation using the Tyvaso 
Inhalation System, which consists of the Opti-Neb-ir Model 
ON-100/7 (an ultrasonic, pulsed-delivery device) and its 
accessories. Tyvaso is dosed in four separate, equally spaced 
treatment sessions per day, during waking hours. The treat-
ment sessions should be approximately four hours apart.
Initial therapy should begin with three breaths of Tyvaso 
(18 µg of treprostinil), per treatment session, four times daily. 
Table 2 Baseline characteristics of patients entering TRiUMPH13
Characteristic Inhaled TRE  
(n = 115)
Placebo  
(n = 120)
P value
Age, years 55 (20–75) 52 (18–75) 0.056
Male/female 22/93 22/98 0.88
PAH etiology
  PAH or familial 64 (56) 67 (56) 0.60
  CvD 40 (35) 37 (31)
  Other 11 (9) 16 (13)
Background PAH therapy
  Bosentan 77 (67) 88 (73) 0.29
  Sildenafil 38 (33) 32 (27)
Time on background therapy weeks
  Bosentan 99 ± 79 90 ± 75 0.62
  Sildenafil 65 ± 60 77 ± 69 0.44
Baseline NYHA iii/iv 112/3 118/2 0.62
Baseline 6MwD, meters 346 ± 63 351 ± 69 0.50
Notes: values are mean (range), n, n (%), or mean ± SD. 
Abbreviations: 6MwD, six-minute walk distance; CvD, collagen vascular disease; 
NYHA,  New  York  Heart  Association;  PAH,  pulmonary  arterial  hypertension; 
SD, standard deviation; TRe, treprostinil.Drug Design, Development and Therapy 2012:6 submit your manuscript | www.dovepress.com
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If three breaths are not tolerated, reduce to one or two breaths 
and subsequently increase to three breaths, as tolerated. 
Dosage should be increased by an additional three breaths at 
approximately 1-2 week intervals, if tolerated, until the target 
dose of nine breaths (54 µg of treprostinil) is reached per treat-
ment session, four times daily. If adverse effects preclude titra-
tion to target dose, Tyvaso should be continued at the highest 
tolerated dose. If a scheduled treatment session is missed or 
interrupted, therapy should be resumed as soon as possible at 
the usual dose. The maximum recommended dosage is nine 
breaths per treatment session, four times daily.
warnings and precautions
Safety and efficacy have not been established in patients with 
significant underlying lung disease (such as asthma or chronic 
obstructive pulmonary disease). In patients with low systemic 
arterial pressure, Tyvaso may cause symptomatic hypoten-
sion. Tyvaso may increase the risk of bleeding, particularly 
in patients receiving anticoagulants. Tyvaso dosage adjust-
ments may be necessary if inhibitors or inducers of CYP2C8 
are added or withdrawn. Hepatic or renal insufficiency may 
increase exposure and decrease tolerability.
Additional clinical data
TRiUMPH-i open label extension
Following completion of the 12-week double-blind phase of 
TRIUMPH-I, 206 of the original 235 patients transitioned 
into the long-term, open-label extension trial. Previously 
reported interim data from these patients26 showed that exer-
cise capacity as assessed by 6MWD continued to improve: 
31 (n = 88), 34 (n = 50), and 50 m (n = 17) at 12, 18, and 
24 months, respectively. Improvements in MLWHF global, 
physical and emotional scores were also observed, while 
maintaining a similar adverse event profile.
Transitioning from inhaled iloprost  
to inhaled treprostinil
Given the availability of a longer-acting, effective inhaled 
prostacyclin analog, the potential of transitioning patients 
from the shorter acting iloprost to inhaled treprostinil 
was examined.27 A 24-month, multicenter, prospective, 
  open-label trial was designed to evaluate the long-term safety 
Table 3 Adverse events occurring in the TRiUMPH-i trial13
Adverse events occurring in .3%  
of treprostinil patients
Treatment
Inhaled TRE  
(n = 115)
Placebo  
(n = 120)
Cough 62 (54) 35 (29)*
Headache 47 (41) 27 (23)*
Nausea 22 (19) 13 (11)
Dizziness 20 (17) 18 (15)
Flushing 17 (15) 1 (,1)*
Throat irritation 16 (14) 10 (8)
Pharyngolaryngeal pain 13 (11) 7 (6)
Diarrhea 11 (10) 9 (8)
Notes: values shown are n (%). *P , 0.05.
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in PAH patients (n = 73) of transitioning from a stable dose of 
inhaled iloprost to inhaled treprostinil. Data from an interim 
analysis of 55 patients provided preliminary evidence sup-
porting the safety of rapid transition from inhaled iloprost 
to inhaled treprostinil while maintaining exercise capacity 
and improving quality of life. Overall, patients noted signifi-
cantly improved CAMPHOR (a PH-specific quality of life 
tool) scores after inhaled treprostinil treatment compared 
with baseline values on iloprost treatment. In addition, the 
total time spent per day administering inhaled treprostinil 
was reduced by 66% (81 minutes) compared with that for 
iloprost at baseline. Significant improvement in median 
6MWD was observed after 12 weeks of inhaled treprostinil 
therapy (426 m vs 388 m at baseline on iloprost; P = 0.002). 
Significant improvements in NT-proBNP were also 
observed at 6 and 12 weeks of treprostinil therapy 
(519 and 419 pg/mL vs 580 pg/mL at baseline on iloprost; 
P , 0.01 for both).
Treprostinil delivery via metered  
dose inhaler
Based on data indicating that a therapeutic dose of trepro-
stinil could be delivered in a single breath,17 Voswinckel 
and colleagues28 evaluated the acute hemodynamic effects 
of the drug delivered by a metered dose inhaler (MDI). 
A total of 39 patients (23 PAH, 16 nonoperable CTEPH) 
were randomized to receive placebo or one of the follow-
ing doses: two puffs of 1,000 µg/mL (30 µg), three puffs 
of 1,000 µg/mL (45 µg) or two puffs of 2,000 µg/mL 
(60 µg). Acute hemodynamic effects were compared to 
inhaled nitric oxide. Doses of 30, 45, and 60 µg of inhaled 
treprostinil reduced PVR from 575 ± 104 dynes to 
494 ± 109 dynes, from 964 ± 184 dynes to 720 ± 229 dynes, 
and from 667 ± 149 dynes to 530 ± 132 dynes, respectively 
(mean ± 95% confidence interval). Mean PAP was 
decreased in response to 30, 45, or 60 µg of inhaled 
treprostinil from 40.1 ± 4.9 mmHg to 33.3 ± 4.4 mmHg, 
from 50.4 ± 6.2 mmHg to 38.1 ± 8.4 mmHg and from 
39 ± 4.8 mmHg to 32.2 ± 4.9 mmHg, respectively. These 
acute effects on hemodynamics were comparable with 
inhaled nitric oxide at 20 ppm. Interestingly, CTEPH 
patients responded as well as PAH patients. No worsening of 
ventilation/perfusion relationships, as assessed by the multi-
ple inert gas elimination technique in five patients, were noted 
in response to inhaled treprostinil by MDI. Determination of 
the efficacy and safety of inhaled treprostinil using an MDI 
awaits a long-term randomized controlled trial.
Use of inhaled treprostinil in clinical 
practice: where does it fit?
Based on the results of a well-designed controlled trial, 
inhaled treprostinil is an efficacious treatment in patients 
who have moderately symptomatic pulmonary arterial 
hypertension on background oral therapy. There are 
compelling data to suggest that the presence of moderate 
functional limitations (Class III) and poor exercise capacity 
(,380 m in some retrospective studies) on initial therapy 
portends a poor prognosis.29,30 In addition, the concept of 
treating patients to goal (Class II, improved walk distance) 
has gained traction.31,32 Combination therapy may benefit 
many patients after re-evaluation of clinical effect of the 
first-line treatment (in general after three months of initiat-
ing therapy). Given that the benefits of oral PAH therapies 
on exercise capacity appear to plateau within three to six 
months, this timeframe seems reasonable to decide whether 
to add inhaled treprostinil to oral therapy. Given the effi-
cacy of inhaled treprostinil, coupled with convenience 
and an acceptable side effect profile, it may be tempting 
to some physicians to start this medication earlier in the 
course of the disease or treatment as up-front combina-
tion therapy with an oral agent. However, this specific 
approach has not been tested systematically. Finally, it is 
compelling to consider the replacement of continuously 
parenteral prostacyclin analog therapy with inhaled trepro-
stinil in combination with an oral agent (PDE-5 inhibi-
tor or endothelin receptor antagonist). This approach 
should only be considered by those highly experienced 
in the care of PAH patients. While several patients have 
been transitioned safely from continuous intravenous or 
subcutaneous prostacyclin analogs to regimens containing 
inhaled treprostinil and an oral agent (unpublished data), 
this approach has not been systematically studied to date. 
It may be feasible only in carefully selected patients who 
are able to tolerate intermittent exposure to   prostacyclin   
analogs.
Conclusions
Treprostinil is a highly active prostacyclin analog demon-
strated to have short- and, in the case of parenteral delivery, 
long-term efficacy in PAH. The nature of the molecule, 
including potency, stability, half-life, and the ability to 
be aerosolized lend itself to delivery via an inhaled route 
using an ultrasonic nebulizer. Studies have confirmed the 
robust benefits and safety of inhaled treprostinil and it 
is now a valuable part of the treatment armamentarium. Drug Design, Development and Therapy 2012:6 submit your manuscript | www.dovepress.com
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Based on the in vitro and in vivo pharmacological action 
of treprostinil, namely vasodilatation, prevention of smooth 
muscle cell proliferation, and its antithrombotic proper-
ties, investigating the role of inhaled treprostinil in other 
forms of non-WHO Group I pulmonary hypertension may 
be warranted.
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